Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Are PARP inhibitors a new standard of care option for MBC patients?

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

Are PARP inhibitors a new standard of care option for MBC patients? ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

The potential of PARP inhibitors in new cancer groups and in combination with...

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

Myeloma highlights from EHA 2019

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain

Myeloma highlights from EHA 2019 ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo...

Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

NILE: Should we give everything to patients with unresectable locally advanced...

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer? ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

Comment: Chemotherapy for frail and elderly patients with advanced...

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Comment: Chemotherapy for frail and elderly patients with advanced gastroesophageal cancer ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

CheckMate-142: Updated data from MSI high metastatic colon cancer patients

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

CheckMate-142: Updated data from MSI high metastatic colon cancer patients ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

Margetuximab for the treatment of HER2-positive breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Margetuximab for the treatment of HER2-positive breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in...

Dr Johannes Ettl - Technical University, Munich, Germany

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer ( Dr Johannes Ettl - Technical University, Munich, Germany )

ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK

ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )

More from ecancer